C4 Therapeutics Financials
CCCC Stock | USD 4.38 0.13 3.06% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 4.78 | 6.3412 |
|
|
Investors should never underestimate C4 Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor C4 Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in C4 Therapeutics.
Net Income |
|
CCCC | Select Account or Indicator |
Understanding current and past C4 Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of C4 Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in C4 Therapeutics' assets may result in an increase in income on the income statement.
Please note, the presentation of C4 Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, C4 Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of C4 Therapeutics' management manipulating its earnings.
C4 Therapeutics Stock Summary
C4 Therapeutics competes with Shattuck Labs, Eliem Therapeutics, Prelude Therapeutics, Monte Rosa, and Foghorn Therapeutics. C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. C4 Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 121 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US12529R1077 |
CUSIP | 12529R107 |
Location | Massachusetts; U.S.A |
Business Address | 490 Arsenal Way, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.c4therapeutics.com |
Phone | 617 231 0700 |
Currency | USD - US Dollar |
C4 Therapeutics Key Financial Ratios
Return On Equity | -0.46 | ||||
Operating Margin | (1.84) % | ||||
Price To Sales | 8.91 X | ||||
Revenue | 20.76 M | ||||
Gross Profit | (86.75 M) |
C4 Therapeutics Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 118.3M | 400.1M | 506.8M | 430.8M | 376.5M | 362.8M | |
Other Current Liab | 6.7M | 8.5M | 12.3M | 15.1M | 15.4M | 11.2M | |
Other Liab | 72.7M | 53.6M | 24.4M | 16.9M | 15.2M | 14.4M | |
Net Tangible Assets | (112.0M) | 280.8M | 389.6M | 289.2M | 332.6M | 168.9M | |
Net Debt | (76.8M) | (158.8M) | (33.2M) | 57.4M | (55.6M) | (58.4M) | |
Retained Earnings | (117.5M) | (183.8M) | (267.7M) | (395.9M) | (528.4M) | (502.0M) | |
Accounts Payable | 5.4M | 5.7M | 4.5M | 1.2M | 1.4M | 2.6M | |
Cash | 90.5M | 181.7M | 76.1M | 29.8M | 126.6M | 99.2M | |
Net Receivables | 4.6M | 4.5M | 5.7M | 1.5M | 11.8M | 15.3M | |
Other Current Assets | 1.6M | 9.7M | 21.4M | 9.9M | 5.7M | 9.0M | |
Total Liab | 230.2M | 119.3M | 117.2M | 141.6M | 130.3M | 128.7M | |
Net Invested Capital | (112.0M) | 290.8M | 400.4M | 300.7M | 246.1M | 191.8M | |
Total Current Assets | 96.8M | 381.0M | 325.7M | 287.6M | 271.2M | 272.4M | |
Net Working Capital | 63.1M | 337.2M | 274.4M | 243.0M | 228.4M | 228.4M | |
Short Term Debt | 880K | 2.1M | 2.7M | 11.7M | 10.4M | 5.2M |
C4 Therapeutics Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Net Interest Income | 1.8M | (836K) | (1.8M) | 1.4M | 6.6M | 6.9M | |
Interest Income | 1.8M | 393K | 387K | 3.6M | 8.6M | 9.0M | |
Interest Expense | 2.2M | 1.2M | 2.1M | 2.2M | 1.4M | 1.7M | |
Total Revenue | 21.4M | 33.2M | 45.8M | 31.1M | 20.8M | 31.5M | |
Gross Profit | (26.3M) | (44.3M) | 42.9M | 23.5M | (97.0M) | (92.1M) | |
Operating Income | (35.5M) | (60.4M) | (82.1M) | (129.5M) | (139.0M) | (132.1M) | |
Ebit | (35.5M) | (65.7M) | (81.7M) | (131.9M) | (129.8M) | (123.3M) | |
Research Development | 48.1M | 78.4M | 94.7M | 117.8M | 117.7M | 89.0M | |
Ebitda | (33.9M) | (62.9M) | (78.8M) | (124.3M) | (122.1M) | (116.0M) | |
Income Before Tax | (33.3M) | (67.0M) | (83.9M) | (128.2M) | (131.2M) | (124.7M) | |
Net Income | (34.1M) | (66.3M) | (86.0M) | (126.5M) | (132.5M) | (125.9M) | |
Income Tax Expense | 804K | (626K) | 2.1M | (1.7M) | 1.3M | 1.3M |
C4 Therapeutics Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Investments | (1.6M) | (190.5M) | (188.1M) | 58.4M | 135.7M | 142.5M | |
Change In Cash | 54.2M | 91.2M | (104.9M) | (46.4M) | 97M | 101.9M | |
Free Cash Flow | 54.3M | (67.9M) | (88.2M) | (111.4M) | (108.5M) | (103.1M) | |
Depreciation | 1.6M | 1.6M | 1.5M | 1.7M | 1.9M | 1.7M | |
Other Non Cash Items | 1.1M | 1.6M | 2.1M | 7.3M | 3.5M | 3.3M | |
Capital Expenditures | 1.3M | 650K | 1.3M | 5.5M | 1.7M | 2.4M | |
Net Income | (34.1M) | (66.3M) | (83.9M) | (128.2M) | (132.5M) | (125.9M) | |
End Period Cash Flow | 93.1M | 184.3M | 79.4M | 33.0M | 130.0M | 102.4M | |
Change To Netincome | 2.0M | 10.2M | 21.5M | 30.0M | 34.5M | 36.2M |
CCCC Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining C4 Therapeutics's current stock value. Our valuation model uses many indicators to compare C4 Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across C4 Therapeutics competition to find correlations between indicators driving C4 Therapeutics's intrinsic value. More Info.C4 Therapeutics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At present, C4 Therapeutics' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the C4 Therapeutics' earnings, one of the primary drivers of an investment's value.C4 Therapeutics Systematic Risk
C4 Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. C4 Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on C4 Therapeutics correlated with the market. If Beta is less than 0 C4 Therapeutics generally moves in the opposite direction as compared to the market. If C4 Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one C4 Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of C4 Therapeutics is generally in the same direction as the market. If Beta > 1 C4 Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in C4 Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various C4 Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of C4 Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
C4 Therapeutics November 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of C4 Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of C4 Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of C4 Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing CCCC Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build C4 Therapeutics's daily price indicators and compare them against related drivers.
Information Ratio | (0.11) | |||
Maximum Drawdown | 23.66 | |||
Value At Risk | (7.98) | |||
Potential Upside | 9.57 |
Complementary Tools for CCCC Stock analysis
When running C4 Therapeutics' price analysis, check to measure C4 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy C4 Therapeutics is operating at the current time. Most of C4 Therapeutics' value examination focuses on studying past and present price action to predict the probability of C4 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move C4 Therapeutics' price. Additionally, you may evaluate how the addition of C4 Therapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |